VivoSeq
Oncology

Patients With Advanced Solid Tumors

1

Pipeline Programs↗

278

Active Trials↗

256

Companies Involved↗

Patients With Advanced Solid Tumors is an early-stage landscape with 1 program across 256 companies. The most active players are Shandong New Time Pharmaceutical Co., LTD, Canwell Biotech Limited, Novartis.

Intelligence

Pipeline Metrics

Competitive Density

74/100

Pipeline Velocity

70/100

Mech. Concentration

N/A

Completion Rate

79/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Shandong New Time Pharmaceutical Co., LTD

1 program

Phase 1C

Canwell Biotech Limited

1 program

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

Can016

Canwell Biotech Limited

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

990

clinical trials

Completed446 · 45%
Recruiting189 · 19%
Unknown status144 · 15%
Terminated102 · 10%
Active, not recruiting49 · 5%
Not yet recruiting38 · 4%
Other22 · 2%

Clinical Trials

Trial Activity

990 trials

Study of ZG0895.HCl in Patients With Advanced Solid Tumors
Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1·NCT05877664·60 enrolled
Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
Recruiting·SShandong Boan Biotechnology Co., Ltd·Phase 1·NCT06596915·167 enrolled
Phase I Study of HBT-708 for Patients With Advanced Solid Tumors
Recruiting·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 1·NCT06993870·60 enrolled
APG-2449 in Patients With Advanced Solid Tumors
Recruiting·Ascentage Pharma Group Inc. logoAscentage Pharma Group Inc.·Phase 1·NCT03917043·165 enrolled
A Study of HS-20124 in Patients with Advanced Solid Tumors
Recruiting·HHansoh BioMedical R&D Company·Phase 1·NCT06763159·450 enrolled
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
Recruiting·Sun Pharma Advanced Research Company Limited logoSun Pharma Advanced Research Company Limited·Phase 1·NCT07042100·177 enrolled
PAS-004 in Patients With Advanced Solid Tumors
Recruiting·PPasithea Therapeutics Corp.·Phase 1·NCT06299839·48 enrolled
Study of TRX-920 for Patients With Advanced Solid Tumors
Recruiting·TTaiRx, Inc.·Phase 1·NCT06143774·30 enrolled
A Study of NBL-028 in Patients With Advanced Solid Tumors
Recruiting·NNovaRock Biotherapeutics, Ltd·Phase 1·NCT06223256·270 enrolled
A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
Recruiting·NNingbo Newbay Technology Development Co., Ltd·Phase 1·NCT05036291·120 enrolled
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
Recruiting·SShanghai YingLi Pharmaceutical Co. Ltd.·Phase 1·NCT06096974·60 enrolled
A Study of CBP-1018 in Patients With Advanced Solid Tumors
Recruiting·CCoherent Biopharma (Suzhou) Co., Ltd.·Phase 1·NCT04928612·170 enrolled
A Study of MHB118C Injection in Patients With Advanced Solid Tumors
Recruiting·MMinghui Pharmaceutical (Hangzhou) Ltd·Phase 1·NCT07045454·200 enrolled
ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
Recruiting·33D Medicines (Sichuan) Co., Ltd.·Phase 2·NCT04891198·126 enrolled
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
Recruiting·OOscotec Inc.·Phase 1·NCT07358806·51 enrolled
Page 1 of 66

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)